No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
www.takara-bio.co.jpNo one on the platform currently holds 4974.T.
No tracked institution reports a position in 4974.T as of their last filing.
No one on the platform has traded 4974.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -10.5% | -2.6% | ||||
| Profit Margin % | -23.8% | 6.3% | 8.6% | |||
| Free Cash Flow Margin % | -22.3% | -5.0% | 0.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $43.6B | -11.8% | $9.00 | $9.00–$9.00 | — | 1 |
| 2028 | $46.1B | +5.8% | $20.00 | $20.00–$20.00 | — | 1 |
| 2029 | $48.8B | +5.7% | $28.00 | $28.00–$28.00 | — | 1 |
| 2030 | $51.6B | +5.7% | $33.00 | $33.00–$33.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-13 | $16.10 | $20.10 | +24.8% |
| 2025-02-13 | $6.60 | $-15.71 | -338.0% |
| 2024-11-08 | $1.10 | $12.96 | +1078.2% |
| 2024-08-08 | $-4.50 | $-8.69 | -93.1% |
| -1.82% |
| $1.01T |
| — |
| 3593.THogy Medical Co.,Ltd. | $6660.00 | +0.00% | $143.6B | — |
| 4534.TMochida Pharmaceutical Co., Ltd. | $3280.00 | +0.92% | $116.0B | — |
Source: Financial Modeling Prep · peers by sector/industry